The urokinase plasminogen activator system in angiosarcoma, Kaposi's sarcoma, granuloma pyogenicum, and angioma: An immunohistochemical study

International Journal of Dermatology

Volumn 39, Issue 3, 2000, Pages 188-191

  Thewes, Matthias ^a   Elsner, Elmar ^b   Wessner, Dirk ^b   Engst, Reinhard ^b   Ring, Johannes ^b  

^a Praxis/Lab of Dermatohistopathology   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE; UROKINASE RECEPTOR;

ANGIOGENESIS; ANGIOMA; ANGIOSARCOMA; ARTICLE; BLOOD VESSEL; CONTROLLED STUDY; ENZYME HISTOCHEMISTRY; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; KAPOSI SARCOMA; MALIGNANT TRANSFORMATION; PROTEIN EXPRESSION; PYOGENIC GRANULOMA; RECEPTOR UPREGULATION;

GRANULOMA, PYOGENIC; HEMANGIOMA; HEMANGIOSARCOMA; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; RECEPTORS, CELL SURFACE; SARCOMA, KAPOSI; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033996212     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2000.00950.x     Document Type: Article

References (23)

1. Petersen H, Brunner N, Francis D, et al. Prognostic impact of urokinase receptor and type 1 plasminogen activator in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671-4675.
2. Thewes M, Engst R, Jürgens M, Borelli S. Immunohistochemical analysis of procathepsin L and cathepsin B in cutaneous Kaposi's sarcoma. Int J Dermatol 1997; 36: 100-103.
3. Schmitt M, Harheck N, Wilhelm O, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemostas 1997; 78: 285-296.
4. Cubelis MV, Wun TC, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1990; 9: 1079-1085.
5. Olsen D, Pollanen J, Hoyer-Hansen G. Internalizarion of the urokinase plasminogen activator inhibitor type-1 complex is mediated hy the urokinase receptor. J Biol Chem 1991; 267: 9129-9133.
6. Buo L, Bjornland K, Karlsrud TS, et al. Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines. Anticancer Res 1994; 14: 2445-2451.
7. Duffy MJ, Duggan C, Mulcahy HE, et al. Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease. Clin Chem 1998; 44: 1177-1183.
8. Duggan C, Kennedy S, Kramer MD, et al. Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer 1997; 76: 622-627.
9. Nekarda H, Siewert JR, Schmitt M, Ulm K. Tumor-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 1994; 343: 117.
10. Nozaki S, Endo Y, Kawashin S, et al. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis. Oral Oncol 1998; 34: 58-62.
11. Wagner S, Atkinson MJ, Thanner S, et al. Type-1 plasminogen activator inhihitor in human renal cell carcinoma. J Pathol 1996; 179: 95-99.
12. Cordell JL, Ealini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase anti-alkaline phosphatase (APAAP). J Histochem Cytochem 1984; 32: 219-229.
13. Beil WR. The fibrinolytic system in neoplasia. Sem Throm Haemost 1996; 22: 459-478.
14. Choong PFM, Ferno M, Akerman M, et al. Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. Int J Cancer 1996; 69: 268-272.
15. Cavallaro U, Gasparin G, Soria MR, Maier JA. Spindle cells isolated from Kaposi's sarcoma-like lesions of BKV/ tat-transgenic mice coexpress markers of different cell types. AIDS 1996; 10: 1211-1219.
16. Schnaper HW, Barnathan ES, Mazar A, et al. Plasminogen activators augment endothelial organization in vitro by two distinct pathways. J Cell Physiol 1995; 165: 107-118.
17. Fibbi G, Pucci M, Serni U, et al. Antisense targeting of the urokinase receptor blocks urokinase-dependent proliferation chemoinvasion, and chemotaxis of the human synovial cells and chondrocyres in vitro. Proc Assoc Am Physicians 1998; 110: 340-350.
18. Roth KW, Brandstetter H, Stürzl M. Cellular and molecular features of HIV-associated Kaposi's sarcoma. AIDS 1992; 6: 895-913.
19. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Thromb Haemostas 1995; 74: 429-436.
20. Min HY, Doyte LV, Vitt CR, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngenic mice. Cancer Res 1996; 56: 2428-2433.
21. Wilhelm O, Schmitt M, Höhl S, et al. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 1995; 13: 296-302.
22. Morrison WH, Byers RM, Garden AS, et al. Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma. Cancer 1995; 15: 319-327.
23. Veness M, Cooper S. Treatment of cutaneous angiosarcoma of the head and neck. Anstralas Radiol 1995; 39: 277-281.